Study #2024-1550
A phase 2/3, multicenter, randomized study of raludotatug deruxtecan (R-DXd), a CDH6-directed antibody-drug conjugate, in subjects with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer
MD Anderson Study Status
Enrolling
Treatment Agent
R-DXd, Paclitaxel, Topotecan, PLD
Description
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Cancer
Study phase:
Phase II/III
Physician name:
Shannon Westin
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.